• Skip to main content
  • Skip to primary sidebar
Transfusion News
  • About Us
  • Topics
    • Adverse Events (non-infectious)
    • Blood Donation
    • Cell Therapy
    • Coagulation & Plasma Transfusion
    • Platelet Transfusion
    • Policy and Guidelines
    • Quality Control and Regulatory
    • RBC Transfusion
    • Serology/Genotyping
    • Special Transfusion Situations
    • Transfusion Transmitted Infections
  • Continuing Education
  • Archives
  • Podcasts
  • Question of the Day
  • Search
  • Subscribe to Email Alerts
  • Follow us on
  • Search
  • Subscribe to Email Alerts

Pathogen-Reduction May Help Prevent Alloimmune Platelet Refractoriness

January 4, 2013

Researchers from the University of Washington and Puget Sound Blood Center have demonstrated that pathogen-reduction may be an effective method to prevent alloimmunization among patients receiving platelet transfusions. The findings were presented at the 54th Annual Meeting of the American Society of Hematology (ASH). Using an immunocompetent dog model, Dr. Sherrill Slichter and colleagues evaluated the impact of filter leukoreduction and pathogen-reduction to remove and inactivate antigen-presenting cells. Transfused platelets in a dog model simulated products received by human patients; transfused dogs received platelet-rich plasma, which was generated from whole blood to simulate non-leukoreduced apheresis platelets, or platelet concentrates from whole blood.  Transfused dog recipients were matched with donors and acceptance of donor platelets was monitored over a series of 8 weekly transfusions.  Results suggested that filter leukoreduction followed by pathogen-reduction was successful in reducing activity of antigen-presenting cells and preventing alloimmune platelet refractoriness.  The research team suggests that similar results would be seen in human patients, including those who were immunosuppressed.  Pathogen-reduction is commonly used by European transfusion services, and has been shown to be safe.

Reference

1. Louie J, Boctor F, Chiang J, Anwar Z, Wittenberg A, Gogas E. Efficacy of 5% Albumin and Fresh Frozen Plasma (AFFP) Versus Fresh Frozen Plasma (FFP) only as Replacement Fluid in Plasma Exchange for Thrombotic Thrombocytopenic Purpura (TTP).  Abstract 272 American Society of Hematology Annual Meeting 2012. Atlanta, GA.  http://www.hematology.org/Meetings/Annual-Meeting/Abstracts/5810.aspx, 2012.

Filed Under

  • News
  • Platelet Transfusion

Recommended

  • FDA Guidance for COVID-19 Convalescent Plasma to Remain in Effect

  • WHO Defends Voluntary Blood Donation Policy

  • High-throughput Blood Antigen Array Genotyping for Blood Donors

Show Comments

Comments on this article are closed.

Get the latest news. Subscribe to our mailing list. Sign Up

Primary Sidebar

Latest News

  • Plasma Equivalent to Clotting Factor Concentrates for Initial Resuscitation of Patients with Severe Trauma

  • Personalized Prediction Model of Prophylactic Platelet Transfusions for Preterm Infants

  • Caffeine in Donor Blood Reduces Quality of Stored RBCs

  • Ferritin Levels Needed to Assess Hemoglobin Recovery after Blood Donation

    Question of the Day

    Copyright © 2025 John Wiley & Sons, Inc. All Rights Reserved.
    Privacy Policy

    Association for the Advancement of Blood and Biotherapies Wiley